1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
Species | Human |
Cat.No | ABC-TC3028 |
Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
Product Category | Primary Cells |
Size/Quantity | 1 vial |
Cell Type | Mononuclear Cell |
Shipping Info | Dry Ice |
Growth Conditions | 37 ℃, 5% CO2 |
Source Organ | Peripheral Blood |
Disease | Acute Myeloid Leukemia |
Biosafety Level | 1 |
Storage | Liquid Nitrogen |
Product Type | Diseased Human Peripheral Blood Mononuclear Cells |
Human Acute Myeloid Leukemia Peripheral Blood Mononuclear Cells (Newly Diagnosed) are isolated from the peripheral blood of newly diagnosed acute myeloid leukemia (AML) patients. The mononuclear cell-rich PBMC layer is separated from diluted whole blood by gradient centrifugation. The cell morphology shows a heterogeneous cell population with a single nucleus, including immature myeloid progenitor cells, monocytes and a small number of lymphocytes.Cytogenetic analysis of these cells commonly reveals chromosomal abnormalities such as t(8;21), inv(16), or monosomy 7, depending on the patient. In in vitro culture, this cell population shows the characteristics of coexistence of adherent growth and suspended growth, and some myeloid progenitor cells can differentiate into leukemic blasts with diverse morphologies These cells typically express CD34, CD33, and HLA-DR, detectable via flow cytometry.They are tumorigenic and can initiate leukemic proliferation when engrafted into immunodeficient mice.
When you publish your research, please cite our product as "AcceGen Biotech Cat.# XXX-0000". In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
Human Acute Myeloid Leukemia Peripheral Blood Mononuclear Cells (Newly Diagnosed) can serve as an in vitro cell model to investigate the pathogenesis of de novo AML and developing novel therapeutic strategies. They also provide a platform for investigating immune evasion mechanisms and developing immunotherapies, such as assessing CAR-T/NK cell cytotoxicity and characterizing immune checkpoint expression patterns.